---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062034"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:59:33.484275+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dianthus reports Q3 net loss $14.8M; positive Phase 1 data for DNTH103, cash $189.9M

## Summary
- Net loss of $14.8M ($3.78 per share); R&D expenses $8.0M, G&A $8.7M including $4.0M severance.
- Cash, equivalents, and investments $189.9M at Sept. 30, 2023; runway into Q2 2026.
- Phase 1 data: ~60-day half-life, potent classical complement inhibition, no serious adverse events.
- Plan to start Phase 2 trials: gMG in Q1 2024, followed by MMN (1H24) and CIDP (2H24).
- Completed merger with Magenta Therapeutics and $72M private placement led by Fidelity and others.

## SEC filing metadata
- accession: 0000950170-23-062034
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017023062034/0000950170-23-062034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017023062034/dnth-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062034
- JSON: https://secwatch.observer/filing/0000950170-23-062034.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062034.txt

## Key facts
- Earnings Releases
  Dianthus Therapeutics, Inc. /DE/ reported third quarter ending September 30, 2023 results: net income $14.8 million, EPS $3.78 net loss per share (basic and diluted).
  - Period: third quarter ending September 30, 2023
  - Net income: $14.8 million
  - EPS: $3.78 net loss per share (basic and diluted)
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2023 was $14.8 million or $3.78 net loss per share (basic and diluted).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000095017023062034/0000950170-23-062034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.